Understanding how to improve responses to cancer immunotherapy
Official title: Determinants of response to cancer immunotherapy
Funded at Fred Hutchinson Cancer Center · NIH-11100664 · Data updated 2026-11-12
This study is looking at what helps or hinders cancer patients from responding well to immunotherapy treatments, especially those that use immune checkpoint inhibitors, to find better ways to personalize these therapies and improve outcomes for everyone.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $1,002,984 |
| NIH project number | 7R35CA253175-04 |
| Project ID | NIH-11100664 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients with advanced cancer who are undergoing immunotherapy treatments.
✕Less likely to help
Patients with early-stage cancer or those not receiving immunotherapy may not benefit from this research.
What this research studies
This research investigates the factors that influence how well patients respond to cancer immunotherapy, particularly focusing on immune checkpoint inhibitors. By utilizing advanced techniques like single-cell RNA sequencing, the study aims to identify specific immune cells and pathways that either promote or hinder effective treatment responses. The researchers will explore combination therapies that target immunosuppressive cells to enhance the effectiveness of existing treatments. This work is crucial for developing personalized immunotherapy strategies that could lead to better outcomes for cancer patients.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy treatments that provide longer-lasting responses for cancer patients.
How similar studies have gone: Previous research has shown promise in enhancing immunotherapy responses through combination therapies, indicating that this approach could yield significant advancements.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Fong, Lawrence — Fred Hutchinson Cancer Center
- Study coordinator: Fong, Lawrence
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.